{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dabigatran+dose+1&page=2", "query": { "intervention": "dabigatran dose 1", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dabigatran+dose+1&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T00:05:26.520Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02102633", "title": "Drug Interaction Study Between Bosutinib And Dabigatran", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Dabigatran", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "21 Years to 55 Years" }, "enrollment_count": 27, "start_date": "2014-05", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-06-24", "last_synced_at": "2026-09-30T00:05:26.520Z", "location_count": 1, "location_summary": "DeLand, Florida", "locations": [ { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02102633" }, { "nct_id": "NCT02744092", "title": "Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Venous Thromboembolism", "Deep Vein Thrombosis (DVT)", "Pulmonary Embolism (PE)", "Blood Clot" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Edoxaban", "type": "DRUG" }, { "name": "Dabigatran", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Dalteparin", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Fondaparinux", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 811, "start_date": "2016-12-13", "completion_date": "2021-02-22", "has_results": true, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-09-30T00:05:26.520Z", "location_count": 151, "location_summary": "Chula Vista, California • Fremont, California • Fresno, California + 104 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02744092" }, { "nct_id": "NCT07190430", "title": "A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "PF-08049820", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Dabigatran Etexilate", "type": "DRUG" }, { "name": "Portia (EE and LN) or equivalent oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2025-10-03", "completion_date": "2025-12-15", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-30T00:05:26.520Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07190430" }, { "nct_id": "NCT00152971", "title": "Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthroplasty, Replacement, Knee", "Thromboembolism" ], "interventions": [ { "name": "Dabigatran Dose 1 - day 2 to completion", "type": "DRUG" }, { "name": "Dabigatran Dose 1 - day 1", "type": "DRUG" }, { "name": "Dabigatran Dose 2 - day 2 to completion", "type": "DRUG" }, { "name": "Dabigatran Dose 2 - day 1", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2615, "start_date": "2004-11", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-05-05", "last_synced_at": "2026-09-30T00:05:26.520Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00152971" }, { "nct_id": "NCT04764851", "title": "Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-Interactions" ], "interventions": [ { "name": "ecopipam HCl ~2mg/kg/day", "type": "DRUG" }, { "name": "Cohort 1 Probe Cocktail", "type": "COMBINATION_PRODUCT" }, { "name": "Cohort 2 Probe Cocktail", "type": "COMBINATION_PRODUCT" }, { "name": "Cohort 3 Probe Cocktail", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Emalex Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2021-02-18", "completion_date": "2021-05-07", "has_results": false, "last_update_posted_date": "2021-05-24", "last_synced_at": "2026-09-30T00:05:26.520Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04764851" }, { "nct_id": "NCT06615596", "title": "Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Atrial Fibrillation (AF)" ], "interventions": [ { "name": "discontinue anticoagulation therapy", "type": "BEHAVIORAL" }, { "name": "Anticoagulant drugs", "type": "DRUG" }, { "name": "Catheter Ablation", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "PROCEDURE" ], "sponsor": "China National Center for Cardiovascular Diseases", "sponsor_class": "OTHER_GOV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3160, "start_date": "2025-08-05", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-30T00:05:26.520Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06615596" }, { "nct_id": "NCT02666742", "title": "DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ventricular Tachycardia", "Premature Ventricular Contraction", "Stroke" ], "interventions": [ { "name": "DOAC", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kansas City Heart Rhythm Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 246, "start_date": "2017-02-16", "completion_date": "2021-04-30", "has_results": true, "last_update_posted_date": "2022-08-22", "last_synced_at": "2026-09-30T00:05:26.520Z", "location_count": 4, "location_summary": "Kansas City, Kansas • Overland Park, Kansas • The Bronx, New York + 1 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "The Bronx", "state": "New York" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02666742" }, { "nct_id": "NCT00157248", "title": "Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atrial Fibrillation", "Stroke" ], "interventions": [ { "name": "dabigatran etexilate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2003-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-05-19", "last_synced_at": "2026-09-30T00:05:26.520Z", "location_count": 12, "location_summary": "La Mesa, California • Pensacola, Florida • Port Charlotte, Florida + 9 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Pensacola", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00157248" }, { "nct_id": "NCT05438303", "title": "Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "AZD9833", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Dabigatran Etexilate", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "50 Years to 70 Years · Female only" }, "enrollment_count": 59, "start_date": "2022-06-13", "completion_date": "2022-12-13", "has_results": false, "last_update_posted_date": "2023-01-12", "last_synced_at": "2026-09-30T00:05:26.520Z", "location_count": 2, "location_summary": "Long Beach, California • Berlin, New Jersey", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Berlin", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05438303" }, { "nct_id": "NCT03539055", "title": "Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atrial Fibrillation", "Device Related Thrombus", "Left Atrial Appendage Thrombosis", "Watchman LAA Closure Device" ], "interventions": [ { "name": "Dabigatran Etexilate Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2018-09-01", "completion_date": "2024-02-29", "has_results": true, "last_update_posted_date": "2025-06-10", "last_synced_at": "2026-09-30T00:05:26.520Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03539055" } ] }